Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
0.7989
+0.0007 (0.09%)
At close: May 12, 2025, 4:00 PM
0.8099
+0.0110 (1.38%)
After-hours: May 12, 2025, 7:34 PM EDT
Esperion Therapeutics Stock Forecast
ESPR's stock price has decreased by -63.52% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Esperion Therapeutics stock have an average target of 5.93, with a low estimate of 2.50 and a high estimate of 16. The average target predicts an increase of 642.27% from the current stock price of 0.80.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Esperion Therapeutics stock from 7 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
Buy | 1 | 2 | 2 | 3 | 3 | 3 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 1 | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Needham | Needham | Strong Buy Maintains $5 → $4 | Strong Buy | Maintains | $5 → $4 | +400.69% | May 7, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +1,902.75% | Apr 25, 2025 |
Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +525.86% | Apr 25, 2025 |
Goldman Sachs | Goldman Sachs | Hold Maintains $4 → $3 | Hold | Maintains | $4 → $3 | +275.52% | Apr 17, 2025 |
Needham | Needham | Strong Buy Reiterates $5 | Strong Buy | Reiterates | $5 | +525.86% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
351.25M
from 332.31M
Increased by 5.70%
Revenue Next Year
306.58M
from 351.25M
Decreased by -12.72%
EPS This Year
-0.02
from -0.28
EPS Next Year
-0.24
from -0.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 441.5M | 383.8M | 639.5M | ||
Avg | 351.3M | 306.6M | 453.0M | ||
Low | 240.4M | 193.7M | 353.5M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 32.9% | 9.3% | 108.6% | ||
Avg | 5.7% | -12.7% | 47.7% | ||
Low | -27.7% | -44.9% | 15.3% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.42 | -0.02 | 0.37 |
Avg | -0.02 | -0.24 | 0.13 |
Low | -0.43 | -0.52 | -0.03 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | - |
Avg | - | - | - |
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.